Sangamo Therapeutics Stock Investor Sentiment
| SGMO Stock | USD 0.84 0.03 3.55% |
About 59% of Sangamo Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Sangamo Therapeutics suggests that many traders are alarmed. Sangamo Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Sangamo Therapeutics. Many technical investors use Sangamo Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Sangamo |
Sangamo Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sangamo Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Sangamo Therapeutics that are available to investors today. That information is available publicly through Sangamo media outlets and privately through word of mouth or via Sangamo internal channels. However, regardless of the origin, that massive amount of Sangamo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sangamo Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sangamo Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sangamo Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sangamo Therapeutics alpha.
Sangamo Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Sangamo to receive 20M from Astellas Pharma in capsid license agreement ALPMYSGMO | 12/19/2024 |
2 | Sangamo Therapeutics, Inc. Investors Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation | 01/02/2025 |
3 | Disposition of 412584 shares by Macrae Sandy of Sangamo Therapeutics at 1.15 subject to Rule 16b-3 | 01/22/2025 |
4 | Sangamo Therapeutics Receives Buy Rating from HC Wainwright - MarketBeat | 01/27/2025 |
5 | Italian charity seeks EMA approval for rescued gene therapy | 02/05/2025 |
6 | Sangamo Therapeutics Announces Updated Phase 12 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safet... | 02/06/2025 |
7 | Biogen Inc. Q4 Earnings and Revenues Surpass Estimates | 02/12/2025 |
8 | Disposition of 7488 shares by Macrae Sandy of Sangamo Therapeutics at 1.0 subject to Rule 16b-3 | 02/24/2025 |
9 | Sangamo Therapeutics NASDAQSGMO shareholders incur further losses as stock declines 15 percent this week, taking five-year losses to 89 | 02/28/2025 |
10 | Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference | 03/06/2025 |
11 | Sangamo Therapeutics Q4 2024 Earnings EPS of -0.11 Misses Estimate, Revenue Falls Short at 7. ... | 03/17/2025 |
12 | Sangamo Therapeutics Full Year 2024 Earnings Misses Expectations | 03/19/2025 |
Check out Sangamo Therapeutics Hype Analysis, Sangamo Therapeutics Correlation and Sangamo Therapeutics Performance. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.49) | Revenue Per Share | Quarterly Revenue Growth 2.698 | Return On Assets | Return On Equity |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.